Celldex Therapeutics, Inc. (CLDX)
NASDAQ: CLDX · Real-Time Price · USD
25.55
+1.83 (7.72%)
At close: Nov 14, 2025, 4:00 PM EST
25.60
+0.05 (0.20%)
After-hours: Nov 14, 2025, 7:26 PM EST
Celldex Therapeutics Stock Forecast
Stock Price Forecast
The 10 analysts that cover Celldex Therapeutics stock have a consensus rating of "Buy" and an average price target of $43.8, which forecasts a 71.43% increase in the stock price over the next year. The lowest target is $21 and the highest is $67.
Price Target: $43.8 (+71.43%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Celldex Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 2 | 2 | 3 | 3 | 4 | 4 |
| Hold | 3 | 3 | 2 | 2 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 9 | 9 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Barclays | Barclays | Sell Maintains $25 → $21 | Sell | Maintains | $25 → $21 | -17.81% | Nov 11, 2025 |
| Mizuho | Mizuho | Buy Initiates $48 | Buy | Initiates | $48 | +87.87% | Oct 21, 2025 |
| Barclays | Barclays | Sell Initiates $25 | Sell | Initiates | $25 | -2.15% | Oct 13, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $62 | Strong Buy | Maintains | $62 | +142.66% | Sep 17, 2025 |
| Wells Fargo | Wells Fargo | Buy Maintains $44 → $38 | Buy | Maintains | $44 → $38 | +48.73% | Aug 20, 2025 |
Financial Forecast
Revenue This Year
3.40M
from 7.02M
Decreased by -51.58%
Revenue Next Year
3.13M
from 3.40M
Decreased by -7.88%
EPS This Year
-3.55
from -2.45
EPS Next Year
-4.24
from -3.55
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 7.8M | 12.6M | |||
| Avg | 3.4M | 3.1M | |||
| Low | 1.4M | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 10.7% | 270.7% | |||
| Avg | -51.6% | -7.9% | |||
| Low | -80.5% | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -3.22 | -3.69 | |||
| Avg | -3.55 | -4.24 | |||
| Low | -3.81 | -4.69 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.